SRT-2183

SRT-2183 is a small molecule drug that was developed by Sirtris Pharmaceuticals for the treatment of diabetes. It is a member of the sirtuin-activating compounds (STACs) class of drugs, which are designed to activate the sirtuin enzymes. Sirtuins are a family of proteins that regulate cellular processes such as aging, inflammation, metabolism, and stress resistance.

Mechanism of Action

SRT-2183 works by activating the SIRT1 enzyme, a member of the sirtuin family. SIRT1 is involved in the regulation of glucose and insulin production, and its activation can improve insulin sensitivity and glucose tolerance, making it a potential treatment for diabetes.

Development and Clinical Trials

SRT-2183 was developed by Sirtris Pharmaceuticals, a subsidiary of GlaxoSmithKline. It was one of several STACs developed by the company, which also includes resveratrol and SRT-1720.

In preclinical studies, SRT-2183 showed promising results in improving insulin sensitivity and glucose tolerance in mice. However, the drug has not yet been tested in human clinical trials.

Potential Applications

While SRT-2183 was initially developed for the treatment of diabetes, its mechanism of action suggests that it could have potential applications in other diseases as well. For example, SIRT1 activation has been linked to increased lifespan and improved health in several animal models, suggesting that SRT-2183 could potentially be used as an anti-aging drug. Additionally, SIRT1 activation has been shown to reduce inflammation and improve stress resistance, suggesting potential applications in diseases such as arthritis and cardiovascular disease.

See Also

• Sirtuin
• Sirtuin-activating compounds
• Sirtris Pharmaceuticals
• GlaxoSmithKline
• Diabetes

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!